Promega Executive and Leadership Team

William Linton, the Chairman, Chief Executive Officer & President at Promega, directs the overarching strategy and operational execution for the company. Linton guides Promega's mission to provide essential tools for scientific advancement, spanning genomics, protein analysis, and cellular research. This leadership role involves setting the corporate vision and ensuring alignment across all business units to foster innovation and market leadership. Overseeing global operations, the Chairman, Chief Executive Officer & President drives the company's commitment to quality and scientific integrity. By championing research and development initiatives, William Linton directly impacts the company's ability to deliver cutting-edge solutions to the biotechnology and molecular biology sectors. Ultimately, Linton secures Promega's position as a key player in drug discovery and genetic identity markets.

Deanna Schuppel, the Senior Executive Administrator, Chief Executive Officer at Promega, provides critical administrative and operational support to the Chief Executive Officer. Schuppel manages key executive functions, ensuring seamless workflow and efficient execution of strategic initiatives. This role involves coordinating high-level meetings, managing executive communications, and facilitating the operational needs of the CEO's office. Overseeing administrative processes, the Senior Executive Administrator, Chief Executive Officer ensures that executive operations align with Promega's broader business objectives. By optimizing executive support systems, Deanna Schuppel directly contributes to the effective functioning of the company's top leadership. Ultimately, Schuppel supports the strategic direction set forth by the Chief Executive Officer, reinforcing Promega's commitment to scientific innovation.

Chris Yarbro, the Chief Financial Officer at Promega, directs the company's financial planning, reporting, and investment strategies. Yarbro manages fiscal operations, ensuring financial health and supporting Promega's growth in biotechnology and molecular biology markets. This role involves overseeing budgeting, managing capital allocation, and driving financial performance across all departments. Overseeing financial stewardship, the Chief Financial Officer ensures compliance with regulatory standards and optimizes resource utilization. By guiding financial decisions, Chris Yarbro directly contributes to Promega's sustained success in areas like genomics and cellular analysis. Ultimately, Yarbro strengthens the company's financial foundation, enabling continued investment in research and development for drug discovery.

Kristen Yetter, the General Manager and President at Promega, directs operational management and strategic growth for key business segments. Yetter oversees the execution of business plans, ensuring efficiency and productivity across Promega's manufacturing and distribution channels for its biotechnology and molecular biology products. This leadership role involves driving operational excellence and fostering a culture of continuous improvement. Overseeing daily operations, the General Manager and President ensures seamless integration of production, supply chain, and customer support functions. By optimizing operational frameworks, Kristen Yetter directly contributes to Promega's ability to deliver high-quality products in genomics and cellular analysis. Ultimately, Yetter solidifies the company's operational foundation, supporting its mission in drug discovery and genetic identity.

Brian Schiro, the Chief Information Officer at Promega, architects the company's technology infrastructure and digital strategy. Schiro oversees the development and implementation of IT systems that support Promega's extensive portfolio in genomics, protein analysis, and cellular research. This leadership position involves ensuring data security, optimizing network performance, and driving digital transformation across the organization. Overseeing all technology operations, the Chief Information Officer ensures that IT solutions directly support scientific discovery and operational efficiency. By advancing the company's technological capabilities, Brian Schiro directly impacts Promega's ability to innovate in drug discovery and genetic identity. Ultimately, Schiro safeguards the company's digital assets and enhances its competitive edge through robust information systems.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, drives revenue generation and strategic business development initiatives worldwide. Machleidt oversees global sales operations and market expansion, focusing on enhancing Promega's presence in genomics, protein analysis, and cellular research sectors. This position involves forging key partnerships and developing market strategies to maximize revenue streams. Overseeing global commercial efforts, the Global Chief Revenue Officer, Strategic Business Lead ensures alignment between sales strategies and the company's product portfolio. By leading revenue growth, Kara Machleidt directly impacts Promega's market share and financial performance in drug discovery and genetic identity. Ultimately, Machleidt champions the company's commercial success and strategic market positioning.

Ash Anderson, the Chief Medical Officer at Promega, provides critical medical and scientific expertise to guide product development and research initiatives. Anderson oversees the clinical relevance and application of Promega's tools in areas such as genomics, protein analysis, and cellular research. This role involves ensuring that the company's offerings meet the rigorous demands of the healthcare and biotechnology sectors. Overseeing medical strategy, the Chief Medical Officer ensures that Promega's innovations align with clinical needs and regulatory requirements. By contributing medical insights, Ash Anderson directly enhances the value and impact of Promega's solutions in drug discovery and diagnostics. Ultimately, Anderson strengthens the company's scientific credibility and market relevance in health-related fields.